Per a study published in April in Genome Medicine , people who carried certain mutations in their PAM (peptidyl-gylcine alpha-amidating monooxygenase) genes, which are key for processing hormones, were less likely to respond to GLP-1 drugs
A.RahmanS
Sin embargo, muchos pacientes reportan sentirse con ms energa despus de iniciar el tratamiento, lo cual puede explicarse por efectos indirectos relacionados con mejoras en su salud metablica
Understanding common mistakes and implementing preventive strategies is essential for patient safety
Medicaid coverage of GLP-1s for obesity, however, varies by state
This article highlights recent developments in GLP-1 agonist formulations and delivery methods, including advanced injectable formulations (eg, prolonged release), novel oral delivery systems (eg, buccal tablets), and topical formulations (eg, transdermal patches)